PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

World Sepsis Day 2024 Highlights Need for Better Sepsis Treatments

GlobalData emphasises importance of improved clinical trials.

World Sepsis Day, observed annually on 13 September, aims to raise awareness about sepsis, a life-threatening condition that claims millions of lives each year.

Sepsis results from a dysregulated immune response to infection, and currently, no drugs specifically target its underlying causes. GlobalData, a leading data and analytics company, stresses the need for improved clinical trial designs and targeted therapies to address this gap.

According to GlobalData, 14 drugs are in late-stage development for sepsis across eight major markets.

Anaelle Tannen, an Infectious Disease Analyst at GlobalData, highlights the importance of timely diagnosis and rapid treatment initiation for better outcomes. She also notes the lack of funding in sepsis research and hopes increased awareness will drive more investment.

Sepsis can escalate to septic shock, leading to multiple organ failure and death if not promptly treated. Current treatments focus on antibiotics, fluid resuscitation, vasopressors, and supportive care. Tannen points out the urgent need for drugs that specifically target sepsis, as existing treatments only address symptoms.

Key opinion leaders interviewed by GlobalData acknowledge the high failure rate of sepsis drugs in clinical trials, attributing it to inappropriate trial endpoints and heterogeneous study groups.

Notable failures include AM Pharma’s ReCAP and Asahi Kasei’s thrombomodulin alfa trials.

Tannen reflected: “There is a big unmet need for drugs that specifically target sepsis, as currently only symptomatic treatments are available. A lack of understanding of the underlying pathophysiological processes contributes towards this issue.”

Improved trial designs and targeted therapies are essential to overcoming these challenges and improving sepsis treatment.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026